Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +0.95%76 EV-to-EBITDA is 15.13 as of Aug. 09, 2026, which is 9% below its 10-year median of 16.63. GuruFocus rates OSTO:MCAP with a GF Score™ of 76/100 and a GF Value™ of kr573.86 (Fairly Valued). Among 515 Medical Devices & Instruments companies, MedCap AB ranks worse than 51.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MedCap AB's enterprise value is kr8,155 Mil.
MedCap AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr539 Mil. Therefore, MedCap AB's EV-to-EBITDA for today is 15.13.
The historical rank and industry rank for MedCap AB's EV-to-EBITDA or its related term are showing as below:
OSTO:MCAP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.95 Med: 16.63 Max: 25.07
Current: 15.13
During the past 13 years, the highest EV-to-EBITDA of MedCap AB was 25.07. The lowest was 9.95. And the median was 16.63.
OSTO:MCAP's EV-to-EBITDA is ranked worse than 51.65% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.79
vs OSTO:MCAP: 15.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MedCap AB's share price for today is kr533.00.
MedCap AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MedCap AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MCAP vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, MedCap AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MedCap AB's EV-to-EBITDA falls into.
MedCap AB's current Enterprise Value is kr8,155 Mil.
MedCap AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr539 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (OSTO:MCAP) has a EV-to-EBITDA of 15.13 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MedCap AB. This is near median its historical median of 16.63. Over the past decade, MedCap AB's EV-to-EBITDA has ranged from 9.95 to 25.07. According to the industry distribution chart, MedCap AB ranks #266 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 51.7%.
Is MedCap AB's EV-to-EBITDA too high?
MedCap AB's current EV-to-EBITDA of 15.13 is near median its 10-year median of 16.63. Over the past 10 years, this metric has ranged from a low of 9.95 to a high of 25.07. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.79. MedCap AB's value of 15.13 is 2.3% above this industry median. Based on the distribution chart, MedCap AB ranks #266 out of 515 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MedCap AB has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #266 out of 515 companies for EV-to-EBITDA. This places MedCap AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.79. MedCap AB's value of 15.13 is 2.3% above this benchmark. Historically, MedCap AB's own EV-to-EBITDA has ranged from 9.95 to 25.07 over the past decade. While the company's 10-year median is 16.63 vs. the industry median of 14.79, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.79, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current EV-to-EBITDA of 15.13 is 2.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MedCap AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current EV-to-EBITDA is 15.13, which is near median its own 10-year median of 16.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr573.86, compared to a current price of kr533.00 — trading 7.1% below its estimated fair value. The current EV-to-EBITDA is 15.13, which is near median its 10-year median of 16.63 and 2.3% above the Medical Devices & Instruments industry median of 14.79. MedCap AB's overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current EV-to-EBITDA is 15.13 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr533.00 is trading 7.1% below its estimated GF Value™ of kr573.86.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
EV-to-EBITDA: 15.13 (near median its 10-year median of 16.63)
GF Value™: kr573.86 vs. price of kr533.00 (7.1% below fair value)
Industry Position: 2.3% above the Medical Devices & Instruments median (#266 of 515)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
76GF Score
Get the complete analysis for OSTO:MCAP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
